SM5

SM5 is low-dose sg lyophilized peptide for laboratory research only.
It is single-target GLP‑1 agonist with fatty acid modification for extended half-life, suitable for low-dose gradient animal trials, different from dual agonist TT and triple agonist RT series. Dissolve powder with bacteriostatic water;

(1) Mild glycemic stabilization & improve mild insulin resistance

It triggers glucose-dependent insulin secretion and suppresses excessive hepatic glucose output. It steadily smooths fasting and postprandial blood glucose fluctuations, lowers glycated hemoglobin, and carries a low risk of hypoglycemia for mild metabolic disorder research models.

(2) Gentle weight management & mild visceral fat reduction

By slowing gastric emptying and activating satiety signals, it naturally cuts daily calorie intake. It mildly accelerates white fat lipolysis while fully preserving lean muscle mass, delivering slow, steady weight loss for low-dose intervention experiments.

(3) Moderate appetite suppression & curb sugar/fat cravings

It acts on hypothalamic satiety center to prolong post-meal fullness, reduce impulsive craving for high-calorie food, normalize irregular eating rhythm without extreme appetite suppression.

(4) Alleviate mild obesity-related metabolic abnormalities

It optimizes blood lipid indicators, relieves mild fatty liver and slight vascular inflammation caused by excess weight, delivers basic cardiovascular endothelial protection, and improves mild metabolic imbalance without intense physiological fluctuation.